Transdel Pharmaceuticals, Inc. (TDLP.OB) Breakthrough Technology Produces Lucrative Partnership Deals
Transdel Pharmaceuticals, www.transdelpharma.com – developers of the revolutionary Transdel™ transdermal cream drug delivery platform and topical anti-inflammatory Ketotransdel® cream for acute pain, has been generating a buzz throughout the pharmaceutical industry producing rumors that TDLP may be on the verge of announcing some significant news. Rumors that TDLP is close to landing deals within weeks with one or two major companies for an up-front $10M cash and FDA trial-expense deal are circulating rapidly, with online biomedical/financial news portal BioMedReports.com projecting the Company could receive 25% + in royalties. CEO and CFO of TDLP, John Lomoro, a 15-year finance and accounting…